publication date: Jan. 20, 2017
NCI formulary, moonshot and public-private partnerships
By Howard Fingert
Senior medical director in oncology clinical research
Takeda Pharmaceuticals Inc.
Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.
Certainly, the NCI Formulary does offer new opportunities for speed and innovation; however, the resulting research programs will also introduce new challenges that will likely be far from easy, coupled with important opportunities for creative engagement and support from industry collaborators.
Like other investigator-initiated trials, researchers from NCI Cancer Centers will investigate Formulary drugs to develop new knowledge about single agents or combination regimens, and the results will likely add to cancer sciences through publication.
However, the overall goals of the National Cancer Moonshot Initiative do not begin and end with a journal publication; instead, primary goals include introduction of important new therapies that will be broadly accessible and provide clinical utility and/or cures.
Building on recent promising, but largely partial, successes with immune-oncology agents, hundreds of protocols are ongoing with goals to introduce new standards of care. Thus, clinical research conducted through the NCI Formulary may face a daunting task to achieve outcomes that differentiate from other emerging regimens, and to provide the quality of data needed by industry sponsors for decision-making to … Continue reading NCI formulary, moonshot and public-private partnerships
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.